Clinical significance of transmembrane 4 superfamily in colon cancer
Author Information
Author(s): Hashida H, Takabayashi A, Tokuhara T, Hattori N, Taki T, Hasegawa H, Satoh S, Kobayashi N, Yamaoka Y, Miyake M
Primary Institution: Kitano Hospital, Tazuke Kofukai Medical Research Institute
Hypothesis
The expression of MRP-1/CD9, KAI1/CD82, and CD151 in colon cancer may serve as prognostic indicators.
Conclusion
The study found that MRP-1/CD9 and KAI1/CD82 expressions are associated with better survival rates, while CD151 expression correlates with poorer outcomes in colon cancer patients.
Supporting Evidence
- 82 carcinomas (43.8%) were MRP-1/CD9-positive.
- 63 carcinomas (43.2%) were KAI1/CD82-positive.
- 81 carcinomas (55.5%) were CD151-positive.
- Patients with MRP-1/CD9-positive tumors had a 3-year survival rate of 98.1%.
- Patients with KAI1/CD82-positive tumors had a 3-year survival rate of 98.2%.
- Patients with CD151-positive tumors had a 3-year survival rate of 78.5%.
Takeaway
This study looked at three proteins in colon cancer to see if they can help predict how well patients will do. Some proteins are linked to better survival, while one is linked to worse survival.
Methodology
A retrospective study analyzing the expression of MRP-1/CD9, KAI1/CD82, and CD151 in tumor samples from colon cancer patients using immunohistochemical and RT-PCR methods.
Potential Biases
Potential bias in patient selection and interpretation of immunohistochemical results.
Limitations
The study is retrospective and may be subject to selection bias.
Participant Demographics
Median age of patients was 62.8 years, with 84 men and 62 women.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website